FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997552014> ?p ?o ?g. }

• W1997552014 endingPage "467" @default.
• W1997552014 startingPage "461" @default.
• W1997552014 abstract "The epidermal growth factor receptor (EGFR) is a validated target in head and neck squamous cell carcinoma (HNSCC). In recurrent and/or metastatic (R/M) HNSCC, resistance to anti-EGFR therapy inevitably occurs. Downstream activation of the PI3K/Akt/mTOR pathway is an established resistance mechanism. Concurrent mTOR blockade may improve efficacy of anti-EGFR therapy. Erlotinib 150 mg daily and temsirolimus 15 mg weekly were administered to patients with platinum-refractory R/M HNSCC and ECOG performance status 0–2. The primary endpoint was progression-free survival (PFS). Correlative studies determined PIK3CA and HRAS mutation status; p16, EGFR, pS6K, pAkt and PTEN expression; and pre- and post-treatment plasma levels of 20 immunomodulatory cytokines. Twelve patients enrolled; six withdrew within 6 weeks due to toxicity or death, prompting early closure of the trial. Grade ⩾ 3 toxicities included fatigue, diarrhea, gastrostomy tube infection, peritonitis, pneumonia, dyspnea, and HN edema. Median PFS was 1.9 months. Median overall survival was 4.0 months. Six/12 tumors were p16(+), 9/11 lacked measurable PTEN expression, and 1/12 harbored a PIK3CA mutation. On exploratory analysis, high baseline plasma VEGF and interferon-gamma levels marginally associated with tumor progression. The combination of erlotinib and temsirolimus was poorly tolerated. Low prevalence of PTEN expression and 8% incidence of PIK3CA mutations indicate biological relevance of this pathway in R/M disease. Investigation of more tolerable combinations of EGFR and PI3K/Akt/mTOR pathway inhibitors in selected HNSCC patients is warranted." @default.
• W1997552014 created "2016-06-24" @default.
• W1997552014 creator A5003097757 @default.
• W1997552014 creator A5010765825 @default.
• W1997552014 creator A5013680322 @default.
• W1997552014 creator A5016127308 @default.
• W1997552014 creator A5020341322 @default.
• W1997552014 creator A5030323121 @default.
• W1997552014 creator A5031107859 @default.
• W1997552014 creator A5044692024 @default.
• W1997552014 creator A5051442834 @default.
• W1997552014 creator A5066408904 @default.
• W1997552014 creator A5071072947 @default.
• W1997552014 creator A5073246708 @default.
• W1997552014 creator A5080102032 @default.
• W1997552014 date "2013-05-01" @default.
• W1997552014 modified "2023-10-16" @default.
• W1997552014 title "A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma" @default.
• W1997552014 cites W1973879983 @default.
• W1997552014 cites W1978916359 @default.
• W1997552014 cites W1980451446 @default.
• W1997552014 cites W1983960952 @default.
• W1997552014 cites W2004439203 @default.
• W1997552014 cites W2004637409 @default.
• W1997552014 cites W2011448791 @default.
• W1997552014 cites W2014674051 @default.
• W1997552014 cites W2015562061 @default.
• W1997552014 cites W2019697444 @default.
• W1997552014 cites W2033780390 @default.
• W1997552014 cites W2038598054 @default.
• W1997552014 cites W2040337823 @default.
• W1997552014 cites W2044407438 @default.
• W1997552014 cites W2062312459 @default.
• W1997552014 cites W2063721051 @default.
• W1997552014 cites W2078233475 @default.
• W1997552014 cites W2084951542 @default.
• W1997552014 cites W2091312795 @default.
• W1997552014 cites W2092420874 @default.
• W1997552014 cites W2097584581 @default.
• W1997552014 cites W2099712757 @default.
• W1997552014 cites W2103134643 @default.
• W1997552014 cites W2103799963 @default.
• W1997552014 cites W2112845420 @default.
• W1997552014 cites W2118073504 @default.
• W1997552014 cites W2131597845 @default.
• W1997552014 cites W2132239791 @default.
• W1997552014 cites W2133671622 @default.
• W1997552014 cites W2143229281 @default.
• W1997552014 cites W2143680521 @default.
• W1997552014 cites W2146950496 @default.
• W1997552014 cites W2149412903 @default.
• W1997552014 cites W2153867442 @default.
• W1997552014 cites W2158734599 @default.
• W1997552014 cites W2159791307 @default.
• W1997552014 cites W2162736389 @default.
• W1997552014 cites W2164547129 @default.
• W1997552014 cites W2165948908 @default.
• W1997552014 cites W2169155283 @default.
• W1997552014 cites W2225154633 @default.
• W1997552014 cites W2595179039 @default.
• W1997552014 cites W2987882970 @default.
• W1997552014 cites W4235642752 @default.
• W1997552014 doi "https://doi.org/10.1016/j.oraloncology.2012.12.016" @default.
• W1997552014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3805493" @default.
• W1997552014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23384718" @default.
• W1997552014 hasPublicationYear "2013" @default.
• W1997552014 type Work @default.
• W1997552014 sameAs 1997552014 @default.
• W1997552014 citedByCount "82" @default.
• W1997552014 countsByYear W19975520142013 @default.
• W1997552014 countsByYear W19975520142014 @default.
• W1997552014 countsByYear W19975520142015 @default.
• W1997552014 countsByYear W19975520142016 @default.
• W1997552014 countsByYear W19975520142017 @default.
• W1997552014 countsByYear W19975520142018 @default.
• W1997552014 countsByYear W19975520142019 @default.
• W1997552014 countsByYear W19975520142020 @default.
• W1997552014 countsByYear W19975520142021 @default.
• W1997552014 countsByYear W19975520142022 @default.
• W1997552014 countsByYear W19975520142023 @default.
• W1997552014 crossrefType "journal-article" @default.
• W1997552014 hasAuthorship W1997552014A5003097757 @default.
• W1997552014 hasAuthorship W1997552014A5010765825 @default.
• W1997552014 hasAuthorship W1997552014A5013680322 @default.
• W1997552014 hasAuthorship W1997552014A5016127308 @default.
• W1997552014 hasAuthorship W1997552014A5020341322 @default.
• W1997552014 hasAuthorship W1997552014A5030323121 @default.
• W1997552014 hasAuthorship W1997552014A5031107859 @default.
• W1997552014 hasAuthorship W1997552014A5044692024 @default.
• W1997552014 hasAuthorship W1997552014A5051442834 @default.
• W1997552014 hasAuthorship W1997552014A5066408904 @default.
• W1997552014 hasAuthorship W1997552014A5071072947 @default.
• W1997552014 hasAuthorship W1997552014A5073246708 @default.
• W1997552014 hasAuthorship W1997552014A5080102032 @default.
• W1997552014 hasBestOaLocation W19975520142 @default.
• W1997552014 hasConcept C121608353 @default.
• W1997552014 hasConcept C126322002 @default.
• W1997552014 hasConcept C143998085 @default.

• next